BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iron Deficiency Anemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Iron Deficiency Anemi
 a\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06287619-591@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 2 readout est. (
 NCT06287619)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 2\, Iron De
 ficiency Anemia.\nStudy: Post-operative Intravenous Iron to Treat Iron-def
 iciency Anemia in Patients Undergoing Cardiac Surgery\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ferric-derisomaltose#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06287619
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05340465-879@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Feraheme (Ferumoxytol): Phase 2 readout est. (NCT05340465)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 2\, Iron Deficiency Anemia.\nStu
 dy: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Suf
 ficiency in Preterm Infants\nEstimated primary completion: 30 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ferumoxytol#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05340465
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462704-591@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT05462704)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Iron De
 ficiency Anemia.\nStudy: Intravenous Versus Oral Iron for Treating Iron-De
 ficiency Anemia in Pregnancy\nEstimated primary completion: 30 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ferric-derisomaltose
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 62704
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179226-591@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT05179226)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Iron De
 ficiency Anemia.\nStudy: Multi-center Trial of Ferric Derisomaltose in Chi
 ldren 0 to <18 Years of Age With Iron Deficiency Anemia\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ferric-derisomaltose#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05179226
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
